Circadian Technologies (ASX:CIR, Opthea) is developing OPT-302, a soluble form of VEGFR-3 that acts a VEGF-C/VEGF-D ‘trap’. Inhibition of VEGF-C/VEGF-D by OPT-302 inhibits angiogenesis and vessel leakage and targets resistance to VEGF-A inhibitors. OPT-302 is being investigated in a Phase 1/2A clinical trial in wet AMD patients in the US.
CEO & Managing Director,
Circadian Technologies (Opthea)
You must be logged in and own this session in order to